-
ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances
-
Student Activism Shifts Underground After University Crackdown on Gaza Encampments
-
Kiss of Life Teases First Winter Single 'Greedy'
-
Surge in Early Social Security Claims Linked to Agency Turmoil
-
Eight-Year-Old Georgia Wins Penrith Valley Public Speaking Competition
-
Panthers Seek NFC South Lead Against Ravens as Baltimore Ends Skid
-
PodcastOne (NASDAQ:PODC) Launches People Pleasers Podcast hosted by Comedians Leah Rudick and Jessica Michelle Singleton
-
5 Fun Date Night Ideas That Don't Cost a Fortune
-
The DEA Laid The Trap - And State Marijuana Operators Took The Bait
-
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 20
-
Ryde Group Ltd Announces Non-Binding Term Sheet for Proposed Minority Investment in Multi Genius Limited and MOU on Technology Collaboration
-
American Resources Corporation and ReElement Technologies Selected as Part of Winning U.S.-Led Consortium for Kenya's Strategic Mrima Hill Critical Minerals Project
-
barq Signs MoU with TenPay Global to Enhance Remittances and Digital Payments in China
-
Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
-
Alset AI Closes Non-Brokered Private Placement Offering
-
Who Does the Best Rhinoplasty in Sarasota?
-
Arrive AI's Pro Forma Stockholders' Equity Now Above Nasdaq Minimum Requirement Following Recent Transactions
-
AI Search Engineers Says Longer AI Mode Questions Mean Professional Service Firms Should Answer Full Client Questions Directly on Their Pages
-
American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
-
Dateline appoints Tony Ferguson as Acting Chairman
-
Closing a Business with Payroll Taxes Owed - Clear Start Tax Explains the Trust Fund Recovery Penalty
-
AsiaFIN Holdings Corp. Appoints Fortune Angel INC as U.S. Reseller Partner to Expand Its Agentic and Robotic Process Automation SaaS Business Across New York and the East Coast
-
Cytta Air Expands Military Contracting Expertise - Appoints Rear Admiral James "Gib" Godwin III to Advisory Board
-
West Midlands Shoppers Urged to Guard Against Black Friday Scams
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Surfshark Adds Real-Time Call Protection to iOS App in Version 5.3.0
-
Samsung Galaxy Buds Active Leak Reveals ANC, Ear-Hook Design and One UI 9.5 Integration
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
Three-year follow-up data from the VenoValve pivotal trial shows sustained clinical improvement and continued patient benefit at 36 months compared to baseline, with statistically significant improvements in disease severity, leg pain, symptoms and quality of life
Company also highlights its next-generation, non-surgical enVVe system and remains on track to enroll the first subject in the TAVVE pivotal study by year-end 2026
IRVINE, CA / ACCESS Newswire / November 20, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, will present three-year data from SAVVE, the U.S. pivotal study of the VenoValve® today at the 53rd Annual Vascular and Endovascular Issues, Techniques and Horizons (VEITH) Symposium in New York City. The data, which will be presented by Dr. David Dexter of Sentara Vascular Specialists, shows sustained, statistically significant improvements in the revised Venous Clinical Severity Score (rVCSS), leg pain and quality-of-life measures in patients with severe chronic venous insufficiency (CVI). The presentation will also highlight enVVe®, the Company's next-generation, non-surgical transcatheter replacement venous valve.

Among the data being presented at VEITH are:
- 5.8-point average improvement in disease severity, as measured by rVCSS, from baseline to 36 months.
- 18-point and 19-point average improvements in venous disease-specific quality of life (VEINES-QOL) and symptoms (VEINES-Sym), respectively.
The rVCSS is a clinically validated scoring system used to track the progression or regression of venous diseases, and a 5.8-point improvement represents a real difference in the daily lives of these patients. Improvement was observed as early as three months following implantation and was sustained through 36 months.
"Patients improved significantly after receiving the VenoValve, and this three-year data shows that those benefits have been sustained," said Robert Berman, Chief Executive Officer of enVVeno Medical. "Demonstrating the long-term viability of our replacement venous valve technology is critically important as we advance enVVe."
enVVe, the Company's next-generation, non-surgical replacement venous valve, builds on the clinical experience gained with VenoValve. Unlike VenoValve, which requires an open surgical procedure and an overnight hospital stay, enVVe is designed to be implanted in a less invasive procedure performed under light sedation, with patients expected to go home the same day.
enVVe will be evaluated in TAVVE (TrAnscatheter Venous Valve Endoprosthesis), a prospective, multicenter pivotal study that received FDA Investigational Device Exemption (IDE) authorization in April 2026. Part 1 of the TAVVE pivotal study will consist of up to 10 patients who will initially be monitored for safety. Following FDA review, the Company plans to proceed to Part 2 of the TAVVE pivotal study, which will evaluate regurgitant flow volume and rVCSS, along with other secondary endpoints. The Company remains on track to enroll the first patient in TAVVE by year-end 2026.
About the enVVe System
The investigational enVVe System is a transcatheter-delivered replacement venous valve designed to restore one-way blood flow in the deep veins of patients with chronic venous insufficiency. An estimated 3 million people in the U.S. suffer from severe deep venous insufficiency, and it remains one of the largest unmet needs in vascular medicine. As venous valves fail, patients often experience chronic pain, swelling, skin changes, recurrent venous leg ulcers and declining quality of life.
Despite the significant burden of deep venous insufficiency, treatment options remain limited and are primarily focused on managing symptoms through compression therapy and wound care rather than addressing the underlying cause: dysfunctional venous valves. The enVVe System is being developed to address this critical treatment gap by helping restore proper directional blood flow to the deep venous system.
About the SAVVE Study
The SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) study is a prospective, single-arm, multicenter U.S. pivotal clinical study evaluating VenoValve in 75 patients with severe chronic venous insufficiency due to deep venous reflux across 21 U.S. clinical centers. The study includes patients with CEAP clinical classifications C4b through C6 and evaluates changes in disease severity, pain, quality of life, symptoms, venous ulcer area and device patency, with follow-up extending to five years.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
INVESTOR CONTACT:
JTC Team, LLC
Jenene Thomas
[email protected]
(908) 824-0775
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
P.Martin--AMWN